Kelley's Optical & Boutique

08/11/2026

ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on innovations in neuro-ophthalmology and ophthalmology, has announced an asset purchase agreement with Accure Therapeutics, a clinical-stage, R&D-driven biopharmaceutical company based in Barcelona, Spain. Under the agreement and upon closing, Oculis will acquire all of Accure’s worldwide development and commercial rights to Privosegtor, an investigational neuroprotective drug candidate for optic neuritis and other neuro-ophthalmic and neuro-axonal diseases, the announcement said. Currently, Privosegtor has not received regulatory approval for commercial use in any country.

ZUG, Switzerland—Oculis Holding AG (Nasdaq: OCS / XICE: OCS), a global biopharmaceutical company focused on innovations in neuro-ophthalmology and ophthalmology, has announced an asset purchase agreement with Accure Therapeutics, a clinical-stage, R&D-driven biopharmaceutical company based in Barc...

08/04/2026

COIMBATORE, India—Aravind Eye Care System, a network of eye hospitals and clinics based in Tamil Nadu, India, and Alcon have launched the Aravind Alcon Global Centre of Excellence (CoE) for Vitreoretinal Surgery Training in Coimbatore, according to an announcement from Alcon. Building on the successful launch of the Global Cataract Centre of Excellence in 2024, Alcon said the new center marks the second phase of its partnership with Aravind to address one of the most critical gaps in global eyecare: access to retina training.

COIMBATORE, India—Aravind Eye Care System, a network of eye hospitals and clinics based in Tamil Nadu, India, and Alcon have launched the Aravind Alcon Global Centre of Excellence (CoE) for Vitreoretinal Surgery Training in Coimbatore, according to an announcement from Alcon. Building on the succe...

07/18/2026

07/14/2026

LONDON and WARREN, N.J.,—Tenpoint Therapeutics, Ltd., a global commercial-stage ophthalmic pharmaceutical company focused on developing treatments to improve vision in the aging eye, has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the review and approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, a once- daily, dual-agent (combination) eye drop for the treatment of presbyopia in adults, according to an announcement from the company.

LONDON and WARREN, N.J.,—Tenpoint Therapeutics, Ltd., a global commercial-stage ophthalmic pharmaceutical company focused on developing treatments to improve vision in the aging eye, has submitted a marketing authorization application (MAA) to the United Kingdom’s Medicines and Healthcare produc...

06/29/2026

CHICAGO—Prevent Blindness, a nonprofit eye health organization, has declared July as Dry Eye Month to raise awareness and educate the public and health care allies about dry eye. The condition occurs when tears do not provide adequate lubrication for the eyes and in some cases can decrease vision. If left untreated, the condition may cause damage to the front of the eye. Prevent Blindness is offering free dry eye resources, including a dedicated webpage, fact sheets and social media graphics, available in English and Spanish, as well as videos from experts and patients.

CHICAGO—Prevent Blindness, a nonprofit eye health organization, has declared July as Dry Eye Month to raise awareness and educate the public and health care allies about dry eye. The condition occurs when tears do not provide adequate lubrication for the eyes and in some cases can decrease vision....

06/24/2026

WATERLOO, Ontario—The Centre for Ocular Research and Education (CORE) has dedicated Issue 90 of Contact Lens Update to the topic of artificial intelligence (AI), focusing on the challenges, opportunities and paths forward. The bi-monthly publication is available at no charge by visiting ContactLensUpdate.com. AI has the potential to rapidly transform myopia management, offering new capabilities for predicting progression, personalizing treatment and improving clinical decision-making, CORE said in an announcement. “AI is not a substitute for clinicians, but it can augment their clinical reasoning,” said Daddi Fadel, adjunct assistant professor at the University of Waterloo and a consultant for CORE.
http://www.visionmonday.com/eyecare/eye-health/article/latest-core-publication-explores-ais-role-in-myopia-management/

WATERLOO, Ontario—The Centre for Ocular Research and Education (CORE) has dedicated Issue 90 of Contact Lens Update to the topic of artificial intelligence (AI), focusing on the challenges, opportunities and paths forward. The bi-monthly publication is available at no charge by visiting ContactLen...

06/19/2026

COLUMBIA, Md.—The Foundation Fighting Blindness, a private funding source for retinal degenerative disease research and its venture arm, the RD Fund (Retinal Degeneration Fund), have announced a $1 million commitment from A Race Against Blindness (RAB) to advance gene-agnostic therapeutic approaches for inherited retinal diseases. The commitment includes $775,000 for the RD Fund and $225,000 for a Foundation Fighting Blindness research award. The $775,000 contribution to the RD Fund will be matched dollar for dollar through the Gordon and Llura Gund Foundation Challenge, unlocking a total of $1.55 million in funding. The challenge doubles all new and increased gifts to the RD Fund, according to the announcement.

COLUMBIA, Md.—The Foundation Fighting Blindness, a private funding source for retinal degenerative disease research and its venture arm, the RD Fund (Retinal Degeneration Fund), have announced a $1 million commitment from A Race Against Blindness (RAB) to advance gene-agnostic therapeutic approach...

06/05/2026

CAMBRIDGE, Mass.—Luminopia Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co. Ltd., a Japanese multinational corporation specializing in consumer products and pharmaceuticals, with a primary focus on eyecare. The agreement grants ROHTO exclusive rights to develop and commercialize Luminopia’s digital therapy for pediatric amblyopia in the Japanese market.

CAMBRIDGE, Mass.—Luminopia Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, announced its first international licensing agreement with ROHTO Pharmaceutical Co. Ltd., a Japanese multinational corporation specializing in consumer products and pharmaceut...

06/05/2026

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners, but time is running out—the deadline for submissions is today, June 5, at 11:59 pm ET. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows readers to highlight their great business support partners and showcase their assistance. Open to all eyecare professionals, the program is looking to spotlight your most successful collaborations and celebrate the crucial support shared during both challenges and opportunities. Our ever-changing workplace renders partnership more vital than ever, and we want to hear your teamwork success stories.

NEWARK, N.J.—The readers of Vision Monday and 20/20 magazine are being asked once again to share nominations for their Ultimate Partners, but time is running out—the deadline for submissions is today, June 5, at 11:59 pm ET. Now in its sixth year, Jobson’s 2026 Ultimate Partners program allows...